EB Beheer Almere B.V.
- Address
- Louis Armstrongweg 88, 1311 RL Almere Stad, The Netherlands
Cardiovascular Disease Research
At EB Beheer Almere B.V., clinical research in cardiovascular diseases focuses on people at elevated risk of serious heart and blood vessel events, especially those without a prior myocardial infarction or stroke. The studies are designed to assess whether new treatments can lower the chance of major cardiovascular complications and improve long-term protection.
- High-risk coronary heart disease prevention
- Reduction of myocardial infarction and ischemic stroke risk
- Evaluation of treatment benefit alongside optimized lipid-lowering care
These trials aim to test the effectiveness of therapies such as evolocumab in preventing first-time major cardiovascular events in vulnerable adults.
Nutritional and Metabolic Disease Research
Research in nutritional and metabolic diseases at this site includes studies in adults with atherosclerotic cardiovascular disease who also have overweight or obesity. The main goal is to understand whether new treatment approaches can improve cardiovascular outcomes while addressing the broader health risks linked to excess weight and metabolic imbalance.
- Atherosclerotic cardiovascular disease with obesity or overweight
- Testing therapies intended to reduce cardiovascular morbidity and mortality
- Supporting better management of cardiometabolic risk
The MARITIME-CV program reflects this focus by evaluating whether maridebart cafraglutide can improve outcomes when added to standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Amgen Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EB Beheer Almere B.V.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227) | 1 | Unknown | 2023-10-20 | 2023-10-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.